Corporate philanthropy makes exceptional pediatric care and research breakthroughs possible at Boston Children’s.
Your Company Can Save Kids’ Lives
Our corporate partners support a wide range of programs, including:
Community Health
One in three Boston children live at or below the poverty line. A lack of financial resources can lead to physical and mental health problems, developmental delays and disruptions in schooling–all barriers to future success. With help from our corporate partners, Boston Children’s is bridging gaps in care for the most vulnerable families to help young people thrive. For example, we’re helping parents from all backgrounds access early-intervention programs for children showing signs of autism, and assisting families who need food, housing or transportation.
Health Equity
Every child deserves a healthy life. Factors like race, ethnicity, disability, and economic status shouldn’t even enter into the equation. With support from corporate donors, our Sandra L. Fenwick Institute for Pediatric Health Equity and Inclusion is finding new ways to improve health care access, delivery and outcomes for all kids.
Mental Health
Mental illness and suicide rates are rising rapidly among young people–a crisis for many families and society at large. We’ve partnered with Franciscan Children’s to reimagine pediatric mental health care for young people today and generations to come. Our bold new approach combines research, clinical care, training, and family-and-community support in a healing, state-of-the-art campus. Corporate partners are helping us make this vision real—and building a healthier workforce for the future.
Research
With the world's largest pediatric research enterprise and a history of breakthroughs, Boston Children's is focused on eliminating childhood disease. Our 3,000+ researchers, many of them Harvard-affiliated faculty, work tirelessly to discover new treatments and cures for devastating childhood illnesses. Corporate support has fueled many of our discoveries, from a groundbreaking treatment for sickle cell disease to targeted therapies for childhood cancers.
